

477 W. Horton Rd. Bellingham, WA 98226 Phone (360) 933-4892 Fax (360) 933-1197

Patient Name:	
Date of Birth:	Weight:
IV Access:	Height:
Allergies:	

Ocrevus Order Form

Please fax this form, copies of insurance cards, demographics, and supporting clinical documentation to (360) 933-1197 to facilitate an efficient referral. Thank you for choosing Infusion Solutions!

	Multiple Sclerosis	ICD-10: G35			
		ICD-		<u> </u>	
	nt received Ocrevus before? No Yes (d			1	
	3 virus screening (HBsAg and anti-HBc) prior to t		□Positive (contr	raindiaatad)	
	ate performed:	inegative	Positive (conti	amulcateu)	
☐ Initiation infusion a ☐ Mainte mL/hour a at 60 min	(ocrelizumab) **Use 0.2 micron filter for administen: 300 mg/250 ml NS IV on day 1 and 15, then stands as the stands of the stan	start mainten ninutes to a r egin infusion utes; increas rate for	maximum rate of 18 at 100 mL/hour; in e to maximum rate	30 mL/hour. crease to 200 of 300 mL/hour	
	Domg dose. Begin infusion at 40 mL/hour; increase		At 15 min	200 mL/hr	
	L/hour every 30 minutes to a maximum rate of 20	00	At 30 min	250 mL/hr	
	L/hour.		At 60 min	300 mL/hr	
 Premedication: Methylprednisolone: 100 mg IV □ Other steroid/dose: Diphenhydramine: 25mg IV □ 50 mg IV □ Other antihistamine/dose: Acetaminophen: 650 mg PO □ 1000 mg PO Other premedication/dose: Alteplase 2mg IV to declot central IV access per Infusion Solutions protocol as needed for occlusion. Flush line with D5W, 0.9% NaCl and/or Heparin 10 units/ml or 100 units/ml per Infusion Solutions protocol. Lidocaine 1% - up to 0.2ml intradermally PRN (may buffer with sodium bicarbonate 8.4% in 10:1 ratio). Infusion Reaction Management per Infusion Solutions protocol as needed. Mursing Orders: If no central IV access, RN to insert peripheral IV, rotate site as needed, and remove at end of therapy. Monitor for infusion reactions during infusions, and observe for at least 1 hour after completion. Rate adjustment for infusion reactions: Mild to moderate reactions: Reduce the infusion rate to one-half of the rate at which the reaction occurred; maintain reduced rate for at least 30 minutes. If the reduced rate is tolerated, increase the rate as usual. Severe reactions: Interrupt infusion immediately and administer supportive management as needed. After all symptoms have resolved, restart infusion beginning at a rate one-half of the rate at onset of reaction. If 					
Life-threa disabling	ed rate is tolerated, increase the rate as usual. tening reactions: Immediately stop and permaner infusion reaction.	ntly discontin	ue infusion for life-	threatening or	
<u> </u>	Labs: □ □ □Each infusion □Other frequency				
Prescriber Sign	ature		Date		
Please Print Na KEY: ♦ Orde	me ers are initiated unless crossed out by provider.	 □ Chec	k box to initiate ord	er.	

Form # 350 Updated 1/20/2025 -AF